Athira Pharma Reports Reduced Losses Amid Financial Challenges

Athira Pharma, Inc. ( (ATHA) ) has released its Q2 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its investors.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, primarily targeting central and peripheral nervous system degenerative disorders. In its latest earnings report for the quarter ended June 30, 2025, Athira Pharma highlighted its ongoing efforts in drug development, despite facing significant financial challenges. The company reported a net loss of $6.97 million for the quarter, a decrease from the $26.86 million loss in the same period last year, reflecting reduced operating expenses. Key financial metrics included a decrease in research and development expenses to $3.66 million from $22.15 million in the prior year, and a reduction in general and administrative expenses to $3.63 million from $5.87 million. The company’s cash, cash equivalents, and investments totaled $29.8 million as of June 30, 2025, down from $58.78 million at the end of 2024. Looking ahead, Athira Pharma’s management remains focused on advancing its pipeline, particularly the development of ATH-1105, while acknowledging the need for additional funding to support its operations and strategic goals.